BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11251944)

  • 1. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Levin CE; Sellors JW
    Cancer; 2002 Apr; 94(8):2312-4; author reply 2314-6. PubMed ID: 12001136
    [No Abstract]   [Full Text] [Related]  

  • 3. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
    Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
    Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R; Haas M; Shanahan M
    Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
    Mejía A; Salas W
    Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical cancer prevention for all the world's women: genuine promise resides in skilled quality management rather than novel screening approaches.
    Suba EJ; Donnelly AD; Furia LM; Huynh ML; Raab SS;
    Diagn Cytopathol; 2007 Mar; 35(3):187-91. PubMed ID: 17304532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
    J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
    Koong SL; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
    Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
    Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
    Perovic S
    J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
    Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
    Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
    Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
    Reust CE
    J Fam Pract; 2001 Feb; 50(2):175. PubMed ID: 11219567
    [No Abstract]   [Full Text] [Related]  

  • 17. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G; Howard K; Webster A; Chapman JR; Craig JC
    Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alternative cost effectiveness analysis of ThinPrep in the Australian setting.
    Neville AM; Quinn MA
    Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):289-94. PubMed ID: 16029294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
    Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
    Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a tailored intervention to increase screening in HMO women overdue for Pap test and mammography services.
    Lynch FL; Whitlock EP; Valanis BG; Smith SK
    Prev Med; 2004 Apr; 38(4):403-11. PubMed ID: 15020173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.